1,300 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Parametrica Management Ltd

Parametrica Management Ltd purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,300 shares of the biopharmaceutical company’s stock, valued at approximately $1,367,000. Regeneron Pharmaceuticals comprises about 1.6% of Parametrica Management Ltd’s portfolio, making the stock its 17th biggest holding.

A number of other institutional investors also recently made changes to their positions in REGN. Vanguard Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock valued at $8,595,268,000 after purchasing an additional 91,956 shares during the period. Capital International Investors grew its position in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares during the period. International Assets Investment Management LLC grew its position in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its stake in Regeneron Pharmaceuticals by 12.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after acquiring an additional 59,769 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $6.26 during trading hours on Wednesday, reaching $814.74. 63,779 shares of the company’s stock traded hands, compared to its average volume of 521,702. The firm has a market capitalization of $89.53 billion, a price-to-earnings ratio of 20.32, a P/E/G ratio of 3.12 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a twelve month low of $784.96 and a twelve month high of $1,211.20. The business’s fifty day simple moving average is $1,007.57 and its two-hundred day simple moving average is $1,037.30.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 7.48% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on REGN shares. Evercore ISI reduced their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Leerink Partners restated a “market perform” rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, Oppenheimer lowered their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,107.25.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.